🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°
Worldwide
Joined March 2019
- Tweets126K
- Following138
- Followers42.6K
- Likes137K
Pinned Tweet
🚨 #ESMO26 GI Cancer: Top Ten by @OncoAlert 🧬
From organ preservation in dMMR rectal and gastric cancer to RAS(ON) inhibition in pancreatic cancer and bispecifics in biliary tract cancer, our faculty picked the must-know GI abstracts from Madrid 👇
#GICancer #CRCSM
@CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara , @pashtoonkasi
, @GillSharlene
OncoAlert retweeted
How do we advance #BreastCancer early detection, tailored therapies, and survivorship care? Newly updated Breast Cancer Research article collection from the @AmericanCancer family of journals highlights progress & challenges ahead.
💗 acsjournals.onlinelibrary.wi…
#BCAM @OncoAlert
OncoAlert retweeted
Lower overall cancer rates in Hispanic people hide excess liver, gastric, and cervical cancers. In this new editorial, @NarjustFlorezMD and Dr. Barbara Segarra-Vasquez highlight gaps in research for this vulnerable population.
Read more:
acsjournals.onlinelibrary.wi…
@OncoAlert
OncoAlert retweeted
@OncoAlert 🚨 4Sights Abstracts to be presented at #ESMO26 🇪🇸 | #evERA: Promising biomarker insights after CDK4/6i!
In patients with ER+/HER2- advanced #BreastCancer in the post CDK 4/6i setting giredestrant + everolimus demonstrated greater PFS benefit 🆚 SOC endocrine therapy + everolimus, regardless of ctDNA tumor fraction, with benefit observed across ESR1 variants and poor-prognosis molecular subgroups 👇
OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Retrospective Exploratory Biomarker Analyses From evERA Breast Cancer: A Phase III Trial of Giredestrant + Everolimus in Patients With Oestrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer in the Post-CDK4/6 Inhibitor Setting
🎙️ Sara Tolaney @stolaney1
🔬 Exploratory biomarker analysis of phase III evERA (365 ctDNA-evaluable): giredestrant + everolimus vs SOC endocrine therapy + everolimus in post-CDK4/6i ER+, HER2– aBC.
➡️ PFS HR 0.52 (0.39–0.70) with cTF ≥1%; 0.61 (0.40–0.94) with cTF <1%
➡️ ESR1m: PFS HR 0.58 (D538) and 0.35 (Y537)
➡️ TP53m PFS HR 0.65 (0.45–0.93); PIK3CAm 0.55 (0.36–0.83)
✅ Giredestrant + everolimus maintained greater PFS benefit regardless of cTF status, with benefit across all ESR1 variants and poor prognostic subgroups. #BreastCancer
(4Sight Made from Abstracts publicly available at the ESMO website)
Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista @guiandri76
OncoAlert retweeted
🔥🚨@OncoAlert Hot Off The Press
Long-Awaited #BigNews by @AstraZeneca
⭐️#Sunvozertinib (which was approved by @FDA in July 2025) is finally:
✅NOW #AVAILABLE in the US for:
❇️#Advanced non-small cell #LungCancer (#NSCLC) with:
🎯#EGFR #Exon20 insertion mutations.
👇🏻
astrazeneca-us.com/content/a…
🔥🚨@OncoAlert Hot Off The Press
@US_FDA approves:
✅ #Sunvozertinib
For:
🔘Advanced non-small cell #LungCancer (#NSCLC) with:
🎯#EGFR #Exon20 insertion mutations, and disease progression on or after chemotherapy.
⭐️#ORR 46% and #DOR 11.1 months
👇🏻
fda.gov/drugs/resources-info…
OncoAlert retweeted
🔬 #ESMO26 | #GIOncology
From RAS-targeted therapies to evolving immunotherapy strategies, key trials addressing clinically relevant questions across GI cancers.
Great to contribute to this Top 10 selection with my colleagues from the @OncoAlert GI Faculty!
🚀 See you soon!
🚨 #ESMO26 GI Cancer: Top Ten by @OncoAlert 🧬
From organ preservation in dMMR rectal and gastric cancer to RAS(ON) inhibition in pancreatic cancer and bispecifics in biliary tract cancer, our faculty picked the must-know GI abstracts from Madrid 👇
#GICancer #CRCSM
@CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara , @pashtoonkasi
, @GillSharlene
OncoAlert retweeted
What is happening in GU Oncology at #ESMO26 _
Here is a Great list from our collaborators at @OncoAlert 🚨and with many of our #GlobalForum26 #PROSCA26 #BLADDR26 #RENALC26
Inviting you to follow our Mirrors of Medicine ESMO26 Coverage!!
🚨 #ESMO26 GU Oncology — Top picks by OncoAlert 🎯
#BladderCancer : VOLGA, KEYNOTE-B15, ENERGIZE, KEYNOTE-866
#ProstateCancer: DASL-HiCaP, CAPItello-281, PROTEUS
#KidneyCancer: LITESPARK-011 & -012, ivonescimab, PE-PE, SWOG S2200, XmAb819
Our Participating Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger , @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi , @AmandaNizamMD, @drenriquegrande, @nataliagandur
@AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun , @ravikanesvaran , @BraunMDPhD, @EfstathiouEleni, @mzugman , @crisbergerot, @ElisaAgostinett, @to_be_elizabeth, @MarioBalsaMD, @BRicciutiMD, @HHorinouchi, @UOzkerim, @p_ciracimd, @DrMirallas , @sonpavde , @Dr_Oncologista
OncoAlert retweeted
Looking forward to this one at #ESMO26 👀
FOURLIGHT-1: a CDK4-selective inhibitor beating standard options after CDK4/6i progression (PFS HR 0.60) with only 4% discontinuing for toxicity. Could this be the next step in our post-CDK4/6i sequence? #BreastCancer
Stay tuned for @mirrorsmedicine Coverage of ESMO!
OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Efficacy and Safety of Atirmociclib + Fulvestrant in Patients With HR+/HER2– Advanced/Metastatic Breast Cancer Who Progressed on Prior CDK4/6 Inhibitor in a Randomized Phase 2 Study (FOURLIGHT-1)
@antgiorda
🔬 Randomized phase 2 (n=263): atirmociclib + fulvestrant vs investigator’s choice (fulvestrant or everolimus + exemestane) in HR+/HER2– mBC after prior CDK4/6i. Primary: investigator-assessed PFS.
➡️ Median PFS 9.4 vs 6.6 mo; HR 0.60 (0.440–0.825); 1-sided p=0.0007
➡️ ORR in patients with measurable disease: 19.3% vs 11.3%; CBR: 61.9% vs 46.0%
➡️ Atirmociclib discontinuation due to TRAEs: 4.0%; most common TRAE neutropenia (46.4%)
✅ First next-generation CDKi to show significant and clinically meaningful PFS improvement after prior CDK4/6i, with a manageable safety profile. #BreastCancer
🎙️ Antonio Giordano
(4Sight Made from Abstracts publicly available at the ESMO website)
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista @guiandri76
OncoAlert 4Sight Abstracts to be Presented at #ESMO26
FOLFIRI Plus Ramucirumab Versus Paclitaxel Plus Ramucirumab as Second-Line Therapy for Taxane-Pretreated Patients With Advanced or Metastatic Gastroesophageal Adenocarcinoma: Final Results of the Phase III IKFs602/AIO RAMIRIS Study
🔬 Phase III (n=317): FOLFIRI + ramucirumab vs paclitaxel + ramucirumab, second-line, in taxane-pretreated advanced GEA. Co-primary endpoints: OS and ORR.
➡️ Median OS 8.7 vs 7.5 mo; HR 0.95; p=.33
➡️ ORR 25.3% vs 22.6% (p=.29); median PFS 5.5 vs 3.7 mo, HR 0.7 (p=.003)
➡️ Grade 3–5 AEs 70% vs 68%
✅ Co-primary endpoints were not met; PFS was clearly improved, supporting personalized treatment decisions in taxane-pretreated advanced GEA.
🎙️ Magdalena Scheck
(4Sight Made from Abstracts publicly available at the ESMO website)
Pinging OncoAlert Faculty
@CathyEngMD, @BenWestphalen, @graokane, @NiuSanford,
, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara,
OncoAlert retweeted
Disease-free survival and overall survival after neoadjuvant immunotherapy in mismatch repair-deficient colon cancer in the Netherlands: results of the single-arm, multicentre, phase 2, NICHE-2 trial
#cancer #oncology #MedX @OncoAlert
thelancet.com/journals/lance…
OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Final Protocol-Prespecified Analysis of the Phase 3 KEYNOTE-564 Trial of Adjuvant Pembrolizumab Versus Placebo in Clear Cell Renal Cell Carcinoma (ccRCC)
@DrChoueiri
@tompowles1
@HowardGurney
🔬 Phase 3 (n=994): adjuvant pembrolizumab vs placebo after nephrectomy in ccRCC at high risk of recurrence. Final prespecified analysis; median follow-up 85.9 mo.
➡️ DFS HR 0.68 (0.56–0.82); 7-yr DFS 57.2% vs 44.6%
➡️ OS HR 0.70 (0.53–0.92); 7-yr OS 82.3% vs 76.6%
➡️ No new serious treatment-related AEs
✅ DFS and OS benefits remained consistent with earlier reports, supporting adjuvant pembrolizumab as standard treatment for ccRCC at increased risk of recurrence. #KidneyCancer
🎙️ Toni Choueiri
👥 Naomi Haas · Thomas Powles · Piotr Tomczak · Se Hoon Park · Balaji Venugopal · Stefan Symeonides · Thomas Ferguson · Yen-Hwa Chang · Jae-Lyun Lee · Piotr Sawrycki · Naveed Sarwar · Howard Gurney · Marine Gross-Goupil · John Burke · Gurjyot Doshi · Jerry Cornell · Joseph Burgents · Rodolfo Perini
(4Sight Made from Abstracts publicly available at the ESMO website)
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper
OncoAlert retweeted
There’s a lot happening in #BreastCancer treatment. Looking for a breakdown?
🎙️ On #CancerSpeak, Drs. @oreganruth & @KalinskyKevin discuss the latest advances shaping care, from treatment de-escalation to emerging therapies.
🔗: cancerspeak.podbean.com/e/to…
@OncoAlert #BCSM
News from industry!
🚨 New option for EGFR exon 20 insertion NSCLC 🫁
Sunvozertinib (ZEGFROVY®) is now available in the US after progression on platinum chemo. It’s the only approved oral single-agent targeted therapy in this setting.
📊 WU-KONG1B
➡️ ORR 46%
➡️ Median DoR 11.1 mo
➡️ 72% of responders sustained ≥6 mo
Exon 20 remains one of the hardest EGFR subtypes to treat, with 5-yr OS as low as 8%. An oral option matters.
#LungCancer #NSCLC #OncoAlert
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers
OncoAlert retweeted
We use AIs every day, but how often do we have long-term head-to-head data? GIM3-FATA at #ESMO26: upfront vs switch made no difference, while exemestane trailed anastrozole on DFS (HR 1.23) with similar OS. Can’t wait for the discussion 🔥 #BreastCancer Stay tuned for
@mirrorsmedicine
Coverage of ESMO!
OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Final Analysis of the GIM3 FATA Trial: Treatment Schedule and Three Aromatase Inhibitors in Postmenopausal HR+ Early Breast Cancer
@PietroDePlacido
@antoniorusso_pa
@delmastro_lucia
@MicheleDelauren
@fperrone62
🔬 Randomized trial (n=3697): 5 years of anastrozole, exemestane or letrozole, upfront or after 2 years of tamoxifen. Co-primary: DFS by schedule and by AI.
➡️ Upfront vs switch: DFS HR 0.95 (0.82–1.09); OS HR 0.88 (0.74–1.06)
➡️ 10-year DFS 79.1% anastrozole, 76.6% letrozole, 74.2% exemestane (global p=0.028)
➡️ Exemestane vs anastrozole: adjusted DFS HR 1.23 (1.04–1.46). 10-year OS across AIs: no statistically significant difference (p=0.25)
✅ No schedule superior; exemestane associated with worse DFS. Choice should be individualized by tolerability, comorbidities and cost. #BreastCancer
🎙️ Pietro De Placido
👥 Laura Arenare · Erica Pietroluongo · Giancarlo Bisagni · Maria Sarobba · Antonio Russo · Ferdinando Riccardi · Lucia Del Mastro · Antonio Pazzola · Francesco Cognetti · Jennifer Foglietta · Stefania Gori · Francesco Nuzzo · Adriano Gravina · Michelino De Laurentiis · Roberto Bianco · Grazia Arpino · Sabino De Placido · Ciro Gallo · Francesco Perrone
(4Sight Made from Abstracts publicly available at the ESMO website)
Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista
OncoAlert retweeted
Sunvozertinib finally now available in the US - over one year since its FDA approval on July 2, 2025 for EGFR exon 20 insertion positive NSCLC after prior chemotherapy. Approval based on WU-KONG1B with RR 46%, mDOR 11.1 months.
astrazeneca-us.com/content/a…
OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Retrospective Exploratory Biomarker Analyses From evERA Breast Cancer: A Phase III Trial of Giredestrant + Everolimus in Patients With Oestrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer in the Post-CDK4/6 Inhibitor Setting
🎙️ Sara Tolaney @stolaney1
🔬 Exploratory biomarker analysis of phase III evERA (365 ctDNA-evaluable): giredestrant + everolimus vs SOC endocrine therapy + everolimus in post-CDK4/6i ER+, HER2– aBC.
➡️ PFS HR 0.52 (0.39–0.70) with cTF ≥1%; 0.61 (0.40–0.94) with cTF <1%
➡️ ESR1m: PFS HR 0.58 (D538) and 0.35 (Y537)
➡️ TP53m PFS HR 0.65 (0.45–0.93); PIK3CAm 0.55 (0.36–0.83)
✅ Giredestrant + everolimus maintained greater PFS benefit regardless of cTF status, with benefit across all ESR1 variants and poor prognostic subgroups. #BreastCancer
(4Sight Made from Abstracts publicly available at the ESMO website)
Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista @guiandri76
OncoAlert retweeted
Looking forward to the final OS from postMONARCH at #ESMO26 👀 A 7.5-month numerical OS gain (32.1 vs 24.6 mo) that didn’t reach significance, but with a consistent PFS signal. Eager to hear how @KalinskyKevin and the team interpret it. #BreastCancer
Stay Tuned for @mirrorsmedicine Coverage!
OncoAlert 4Sight Abstracts to be Presented at #ESMO26
1RO: Final Overall Survival Analysis of postMONARCH: Abemaciclib Plus Fulvestrant After Progression on Prior CDK4/6 Inhibitor in HR+, HER2– Advanced Breast Cancer
@KalinskyKevin
@BianchiniGP
@ErikaHamilton9
@DrSGraff
@drsarahsam
@MuozMateu
🔬 Phase 3, double-blind trial (n=368): abemaciclib or placebo plus fulvestrant in HR+, HER2– ABC after progression on prior CDK4/6i + ET. Final OS analysis.
➡️ Median OS 32.1 vs 24.6 mo; HR 0.80 (0.60–1.06); p=0.1145, statistical significance not reached
➡️ Updated PFS HR 0.78 (0.62–0.99); nominal p=0.0390
➡️ Safety consistent with the established abemaciclib profile; no new signals
✅ Numerically longer median OS, not statistically significant. While absolute PFS benefit was modest, overall evidence supports considering abemaciclib-based treatment after disease progression on prior CDK4/6i + ET. #BreastCancer
🎙️ Kevin Kalinsky
👥 Giampaolo Bianchini · Erika Hamilton · Stephanie Graff · Kyong Hwa Park · Rinath Jeselsohn · Umut Demirci · Miguel Martin · Rachel Layman · Sara Hurvitz · Sarah Sammons · Peter Kaufman · Montserrat Muñoz · Jiun-I Lai · Holly Knoderer · Cynthia Sandoval · Aarti Chawla · Bastien Nguyen · Yanhong Zhou · Elizabeth Ravenberg · Lacey Litchfield · Lillian Smyth · Seth Wander
(4Sight Made from Abstracts publicly available at the ESMO website)
Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista
OncoAlert retweeted
🔬 Can radiotherapy change the treatment paradigm for SMARCB1-deficient renal medullary carcinoma?
sciencedirect.com/science/ar…
High Radiographic Response Rates After Metastasis-directed Radiation Therapy in SMARCB1-deficient Renal Medullary Carcinoma
SMARCB1-deficient renal medullary carcinoma (RMC) is a rare, aggressive malignancy with limited treatment options. In the largest reported series of metastasis-directed radiotherapy in RMC, 24 patients received radiation across 52 lesions.
➡️ Radiographic response reached 82%, including 50% complete responses, with local control of 91.3% at 12 months.
✅ These findings suggest potential radiosensitivity and support prospective evaluation of radiotherapy within multimodal treatment strategies, while acknowledging retrospective design limitations and uncertain systemic benefit. #KidneyCancer
@PavlosMsaouel
@ChadTangMD
OncoAlert retweeted
Can three routine blood tests improve risk stratification in advanced prostate cancer?
ascopubs.org/doi/10.1200/CCI…
Development and External Validation of a Machine Learning-Derived Risk Stratification Score for Metastatic Castration-Resistant Prostate Cancer
PROGRESS is a machine learning-informed prognostic score developed to improve risk stratification in metastatic castration-resistant #ProstateCancer (mCRPC).
➡️Combining three routine laboratory measures—PSA, alkaline phosphatase, and AST—the tool consistently distinguished patients with different overall survival outcomes across independent validation cohorts.
➡️ Its simplicity and reproducibility may support clinical decision-making and trial enrichment, although prospective real-world validation remains necessary before widespread implementation in clinical practice.
@LauraCastr83928, @xcraz_1, @josecastillocal
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
OncoAlert retweeted
Looking forward to this presentations at #ESMO26
Long-Term Overall Survival With Abiraterone Acetate Plus Prednisone in the PEACE-1 Phase 3 Trial for De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Long-Term Overall Survival With Abiraterone Acetate Plus Prednisone in the PEACE-1 Phase 3 Trial for De Novo Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
@RayMcDermott1
@BertrandTOMBAL
🔬 Phase 3, 2×2 factorial (n=1173): abiraterone and/or prostate RT added to SOC (ADT ± docetaxel) in de novo mCSPC. Median follow-up 7.7 y.
➡️ Abiraterone: OS HR 0.75 (0.65–0.87); p=0.0001
➡️ ADT + docetaxel ± abiraterone: median OS 4.4 vs 6.2 y; 8-year OS 27.1% vs 40.3%
➡️ High-volume: 8-year OS 20% vs 38%; interaction by metastatic extent p=0.56
✅ Major OS benefit of adding abiraterone to SOC, irrespective of metastatic extent; triplet associated with almost twice as many long-term survivors in some subgroups.
#ProstateCancer
🎙️ Karim Fizazi
👥 Stéphanie Foulon · Joan Carles · Guilhem Roubaud · Ray McDermott · Aude Fléchon · Bertrand Tombal · Stéphane Supiot · Dominik Berthold · Philippe Ronchin · Gabriel Kacso · Gwenaëlle Gravis · Fabio Calabro · Jean-François Berdah · Ali Hasbini · Marlon Silva · Antoine Thiery-Vuillemin · Igor Latorzeff · Loïc Mourey · Brigitte Laguerre · Sophie Abadie-Lacourtoisie · Etienne Martin · Claude El Kouri · Anne Escande · Alvar Rosello · Nicolas Magne · Friederike Schlurmann · Frank Priou · Marie-Eve Chand-Fouche · Salvador Villà Freixa · Muhammad Jamaluddin · Isabelle Rieger · Alberto Bossi
(4Sight Made from Abstracts publicly available at the ESMO website)
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper
OncoAlert retweeted
🧬 NICHE-2 | Phase II | dMMR colon cancer 🇳🇱
👥 111 pts | Nivo + ipi → surgery
🎯 3-y DFS 100%
📈 5-y OS 100%
🩸 ctDNA clearance 82% pre-op
✅ All ctDNA− post-op
⚠️ Single-arm trial
💡 Remarkable long-term outcomes!
🔗 doi.org/10.1016/S0140-6736(2…
@OncoAlert
